FTC Approves Final Order Imposing Conditions on Combination of Pfizer Inc.’s Upjohn and Mylan N.V.

Federal Trade Commission

WASHINGTON, D.C. — Following a public comment period, the Federal Trade Commission recently approved a final order settling charges that the combination of the Upjohn division of pharmaceutical company Pfizer and Mylan N.V. would violate federal antitrust law.

The proposed transaction contemplated that Pfizer Inc. would spin off its Upjohn division—which includes Pfizer’s authorized generic business Greenstone, LLC—and combine it with Mylan to form Viatris Inc.

The complaint, which was first announced in October 2020, alleged that the combination would likely harm current competition in seven generic drug markets and future competition in three generic drug markets.

The final order requires the parties to divest rights and assets in the seven current generic drug markets where harm was likely. It also requires prior Commission approval before Upjohn, Mylan, or Viatris may gain an interest in or exercise control over any third party’s rights in the three future generic drug markets where harm is likely.

READ:  Ocugen Announces Michael Shine as Senior Vice President, Commercial

The Commission vote to approve the final order was 3-2. Chairwoman Rebecca Kelly Slaughter and Commissioner Rohit Chopra voted no.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.